Chinook Therapeutics (KDNY) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chinook Therapeutics stock.
View analyst ratings for Chinook Therapeutics or view top-rated stocks.

3 Wall Street analysts have issued 1 year price targets for Chinook Therapeutics' stock. Their KDNY stock forecasts range from $30.00 to $44.00. On average, they anticipate Chinook Therapeutics' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Chinook Therapeutics or view top-rated stocks among Wall Street analysts.

Chinook Therapeutics' stock was trading at $16.31 at the start of the year. Since then, KDNY shares have increased by 25.3% and is now trading at $20.44.
View the best growth stocks for 2022 here.

Chinook Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,540,000 shares, an increase of 25.1% from the June 30th total of 2,030,000 shares. Based on an average daily trading volume, of 660,300 shares, the days-to-cover ratio is currently 3.8 days.
View Chinook Therapeutics' Short Interest.

Chinook Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Chinook Therapeutics.

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.14. The business earned $2.70 million during the quarter. Chinook Therapeutics had a negative trailing twelve-month return on equity of 23.24% and a negative net margin of 180.48%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."

Chinook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.92%), Candriam S.C.A. (1.58%), Connor Clark & Lunn Investment Management Ltd. (0.22%), Marquette Asset Management LLC (0.07%), SG Americas Securities LLC (0.04%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Company insiders that own Chinook Therapeutics stock include Alan Glicklich, Andrew James King, Davis Jerel, Eric Bjerkholt, Eric Dobmeier, Srinivas Akkaraju, Tom Frohlich and Versant Venture Capital Vii, L.
View institutional ownership trends for Chinook Therapeutics.

Shares of KDNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KDNY stock can currently be purchased for approximately $20.44.

Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $1.13 billion and generates $51.63 million in revenue each year. The company earns $-102,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

Chinook Therapeutics employs 138 workers across the globe.

Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for Chinook Therapeutics is chinooktx.com. The company can be reached via phone at (206) 485-7051 or via email at investors@aduro.com.